TaiMed Biologics (4147) — Capital Reinvestment Ratio
Latest as of December 2025:
0.65x
TaiMed Biologics (4147) has a Capital Reinvestment Ratio of 0.65x as of December 2025, meaning it reinvests 1% of its operating cash flow (NT$25.95 Million) in capital expenditures (NT$16.75 Million). See TaiMed Biologics (4147) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.65x
Capex / Operating Cash Flow
Operating Cash Flow
NT$25.95 Million
TWD
Capital Expenditures
NT$16.75 Million
TWD
Data as of
Dec 2025
Most recent filing
TaiMed Biologics Capital Reinvestment Ratio (2025–2025)
This chart tracks TaiMed Biologics's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for TaiMed Biologics (2025–2025)
Year-by-year Capital Reinvestment Ratio for TaiMed Biologics from 2025 to 2025. For live market cap and broader valuation context, see how much is TaiMed Biologics worth.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.12x | NT$191.14 Million | NT$22.77 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow